Table 1.

Clinical characteristics at randomization of the people with Type 2 diabetes studied

	Rosiglitazone + metformin and insulin	Placebo and insulin
Safety population (n)	162	160
Age (years)	57.2 ± 8.6	56.9 ± 9.1
Sex [M/F, n (%)]	84/78 (52/48)	85/75 (53/47)
Race [white/other, n (%)]	158/4 (98/2)	158/2 (99/1)
Body weight (kg)	88.9 ± 15.3	92.1 ± 16.8
Body mass index (kg/m2)	31.8 ± 4.7	32.5 ± 5.2
Duration from diagnosis (years)	9.2 ± 6.1	8.5 ± 6.0
Prior glucose-lowering drug use [one/two daily at entry, n (%)]	33/129 (20/80)	31/129 (19/81)

Mean ± sd, or n (%).

Baseline blood glucose control data are given in Table 2.